Douglas F. Beach

Dr. Douglas F. Beach is a Clinical Associate Professor of Medicine specializing in Hematology-Oncology at the University of Pennsylvania Perelman School of Medicine. He serves as Director of the CREP/Breast and Ovarian Cancer Program and Associate Program Director of the Internal Medicine Residency. Dr. Beach sees patients at Penn Hematology/Oncology at Pennsylvania Hospital's Abramson Cancer Center and has hospital privileges at both the Hospital of the University of Pennsylvania and Pennsylvania Hospital.

Dr. Beach's research focuses on hematologic malignancies, particularly chronic lymphocytic leukemia (CLL), with numerous publications on novel therapies like ibrutinib and umbralisib. His work bridges clinical trial data with real-world patient outcomes, addressing important questions about treatment efficacy in diverse patient populations. He also conducts research in breast and ovarian cancer through his directorship of the CREP program, and has published on various cancer types including prostate cancer disparities and rare cancer presentations.

Analysis of Dr. Beach's recent publications shows a strong focus on chronic lymphocytic leukemia treatment, particularly examining real-world applications of novel targeted therapies. His research often addresses how clinical trial findings translate to broader patient populations, including those with comorbidities or other factors that might have excluded them from initial trials. He has also published on cancer disparities, rare cancer presentations, and the intersection of various medical conditions with cancer progression.

• Director, CREP/Breast and Ovarian Cancer Program
• Associate Program Director, Internal Medicine Residency
• Clinical Associate Professor of Medicine (Hematology-Oncology)
• Hospital privileges at Hospital of the University of Pennsylvania
• Hospital privileges at Pennsylvania Hospital

Dr. Beach maintains an active clinical practice while contributing significantly to cancer research. His dual focus on hematology-oncology and breast/ovarian cancer programs demonstrates a broad expertise across multiple cancer types. With an exceptional patient satisfaction rating of 4.9/5 based on over 800 reviews, he is highly regarded by both patients and colleagues for his clinical care and research contributions.